Insmed Inc. (INSM), Thursday announced offering of 12.62 million shares at $51.50 per share, to raise approximately $650 million.
The biopharmaceutical company intends to use the proceeds to fund research and development of brensocatib, Arikayce, and treprostinil palmitil inhalation powder, along with their commercialization activities.
Insmed has announced a 30-day option to underwriters to purchase up to an additional 1.89 million shares.
Goldman Sachs & Co. LLC, Leerink Partners, and J.P. Morgan act as the joint-book runners of the offering.
Currently, Insmed's stock is climbing 5.21 percent, to $56.21 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.